NASDAQ · IRMD

iRadimed Corporation

$95.08 +$0.59 (+0.62%) 1D After hours

Key Metrics

$1.21B
Market cap
51.16×
P/E · TTM
$86.28M
Revenue · TTM
$23.61M
Net income
EPS · TTM $1.84
Dividend yield 1.3%
Free cash flow $24.47M
Beta · 1Y 0.59
EBITDA · TTM $31.61M
Gross margin 76.8%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Feb 10
    The stock moved +9.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 10

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.21B
Enterprise value
Shares outstanding12.8M
52-wk range$57.53 – $107.90
Avg volume · 20D50.3K
Net cash
Book value / share$7.68
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About iRadimed Corporation
IPO dateJul 16, 2014
Employees166

iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E51.16
P/S14.00
P/FCF49.35
EV/EBITDA
EV/Sales
Graham №$17.84

Profitability

Gross 76.8%
Operating 35.0%
Net 27.4%
FCF 28.4%
ROE / ROIC 25.5% · 56.0%

Financial Health

Current ratio7.13
Quick ratio6.15
Debt / equity
Debt / EBITDA
Net cash
Working capital$74.30M

Cash Flow · TTM

Operating CF $28.94M
Capex −$4.47M
Free cash flow $24.47M
Buybacks
Dividends paid $15.43M
Shareholder yield 1.3%

Piotroski F-Score

5 / 9
Middling fundamentals · 5 of 9 signals passing

Altman Z-Score

48.9
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$17.84 vs $95.08
Trades 5.3× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings